Related Experiment Video
Updated: Apr 8, 2026

04:42
Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation
Published on: June 26, 2018
15.3K
Midterm Clinical and Radiologic Outcomes after Percutaneous Interspinous Spacer Treatment for Neurogenic Intermittent
Stefano Marcia1, Joshua A Hirsch2, Ronil V Chandra3
1Department of Radiology, SS. Trinità Hospital, Cagliari, Italy.
Journal of Vascular and Interventional Radiology : JVIR
|June 30, 2015
Summary
Percutaneous interspinous process spacer (IPS) treatment offers durable relief for neurogenic intermittent claudication (NIC) pain and disability. This minimally invasive procedure also significantly increases spinal canal and foraminal areas.
Area of Science:
- Neurosurgery
- Orthopedic Surgery
- Minimally Invasive Spine Procedures
Background:
- Neurogenic intermittent claudication (NIC) is a debilitating condition often resulting from lumbar spinal stenosis.
- Conservative treatments for NIC frequently fail, necessitating alternative interventions.
- Percutaneous interspinous process spacer (IPS) implantation is an option for patients with refractory NIC.
Purpose of the Study:
- To assess the midterm clinical and radiologic outcomes of percutaneous interspinous process spacer (IPS) treatment for neurogenic intermittent claudication (NIC).
- To evaluate the durability of treatment effects in patients who have not responded to conservative management.
Main Methods:
- A cohort of 80 patients with confirmed lumbar spinal stenosis and failed conservative treatment underwent percutaneous IPS implantation.
- Clinical outcomes were measured using Visual Analog Scale (VAS) for pain and Oswestry Disability Index (ODI) for function at baseline and up to 3 years post-procedure.
- Radiologic changes, including spinal canal and foraminal cross-sectional areas, were assessed using computed tomography at baseline and 1 year.
Main Results:
- Percutaneous IPS treatment led to significant reductions in VAS and ODI scores at 1 month, with sustained improvements at 1 and 3 years.
- The mean VAS score decreased from 8.1 to 4.4, and the mean ODI score decreased from 23.3 to 11.7.
- Radiologic evaluation at 1 year showed a significant 15% increase in spinal canal and foraminal cross-sectional areas at the treated level.
Conclusions:
- Percutaneous interspinous process spacer (IPS) implantation provides significant and durable pain relief and functional improvement for patients with neurogenic intermittent claudication (NIC) refractory to conservative care.
- The observed clinical benefits are associated with measurable increases in spinal canal and foraminal dimensions, suggesting a mechanism for improved neuroforaminal decompression.

